Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;85(4):341-8.
doi: 10.4065/mcp.2009.0492. Epub 2010 Mar 15.

An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy

Liron Caplan  1 , Cory B Pittman, Angelique L Zeringue, Jeffrey F Scherrer, Kent R Wehmeier, Francesca E Cunningham, Seth A Eisen, Jay R McDonald
Affiliations

An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy

Liron Caplan et al. Mayo Clin Proc. 2010 Apr.

Abstract

Objective: To seek evidence for the association of bisphosphonate use with diffuse musculoskeletal pain (MSKP) in a large national cohort, controlling for conditions associated with MSKP.

Patients and methods: This retrospective cohort study enrolled all US veterans aged 65 years or older with a vertebral or hip fracture who were treated for at least 1 year between October 1, 1998, and September 30, 2006 (N=26,545). All International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, demographics, and pharmaceutical data were obtained from national databases. A composite end point, based on ICD-9-CM codes compatible with diffuse MSKP, was constructed. The primary outcome was time until MSKP. We performed regression analysis using the Cox proportional hazards model, controlling for age, sex, race, alcoholism, depression, anxiety, smoking, recent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use, rheumatic disease, and comorbidity score.

Results: The univariate regression identified an association of bisphosphonate exposure and MSKP (hazard ratio, 1.22; 95% confidence interval, 1.04-1.44). In the multivariate regression, however, patients prescribed a bisphosphonate were not more likely to be assigned an ICD-9-CM code compatible with diffuse MSKP (hazard ratio, 1.10; 95% confidence interval, 0.93-1.30). Consistent with prior studies, we found that female sex, depression, anxiety, comorbidity score, and the presence of a rheumatic disease were all associated with a greater risk of a diagnosis of diffuse MSKP. There was no demonstrable association with statin exposure.

Conclusion: Bisphosphonate use was not associated with a statistically higher rate of MSKP in this cohort. Individual patients may rarely report MSKP while taking bisphosphonates; however, for our studied cohort, incident MSKP does not appear to explain bisphosphonate discontinuation rates.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Study flow diagram. “Censored” refers to those patients who did not have a code for incident musculoskeletal pain (MSKP) at the time of last clinical encounter or termination of the observation period for the data set.
FIGURE 2.
FIGURE 2.
Time-dependent survival plot: time to musculoskeletal pain (MSKP) in patients taking bisphosphonates.
See this image and copyright information in PMC

References

    1. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991;90(1):107-110 - PubMed
    1. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16(suppl 2):S3-S7 - PubMed
    1. Ray NF, Chan JK, Thamer M, Melton LJ., III Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12(1):24-35 - PubMed
    1. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14(12):965-968 - PubMed
    1. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W. The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord. 2007September26;8:97 - PMC - PubMed

Publication types

MeSH terms

Substances